Indiana University, Indianapolis, Indiana, USA.
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S65-87. doi: 10.1016/j.jaci.2011.12.986.
Outcomes of pulmonary physiology have a central place in asthma clinical research.
At the request of National Institutes of Health (NIH) institutes and other federal agencies, an expert group was convened to provide recommendations on the use of pulmonary function measures as asthma outcomes that should be assessed in a standardized fashion in future asthma clinical trials and studies to allow for cross-study comparisons.
Our subcommittee conducted a comprehensive search of PubMed to identify studies that focused on the validation of various airway response tests used in asthma clinical research. The subcommittee classified the instruments as core (to be required in future studies), supplemental (to be used according to study aims and in a standardized fashion), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011.
A list of pulmonary physiology outcomes that applies to both adults and children older than 6 years was created. These outcomes were then categorized into core, supplemental, and emerging. Spirometric outcomes (FEV(1), forced vital capacity, and FEV(1)/forced vital capacity ratio) are proposed as core outcomes for study population characterization, for observational studies, and for prospective clinical trials. Bronchodilator reversibility and prebronchodilator and postbronchodilator FEV(1) also are core outcomes for study population characterization and observational studies.
The subcommittee considers pulmonary physiology outcomes of central importance in asthma and proposes spirometric outcomes as core outcomes for all future NIH-initiated asthma clinical research.
肺生理学结果在哮喘临床研究中占据核心地位。
应美国国立卫生研究院(NIH)研究所和其他联邦机构的要求,召集专家组提供建议,使用肺功能测量作为哮喘结果,以标准化方式评估未来哮喘临床试验和研究中的哮喘结果,以便进行跨研究比较。
我们的小组委员会进行了全面的 PubMed 搜索,以确定专注于验证哮喘临床研究中使用的各种气道反应测试的研究。小组委员会将这些仪器分类为核心(未来研究中需要)、补充(根据研究目的和标准化方式使用)或新兴(需要验证和标准化)。这项工作在 2010 年 3 月由 NIH 组织的研讨会上进行了讨论,并在 2011 年 9 月最终确定。
创建了一份适用于 6 岁以上成人和儿童的肺生理学结果清单。然后将这些结果分为核心、补充和新兴类别。肺活量计结果(FEV1、用力肺活量和 FEV1/用力肺活量比值)被提议作为研究人群特征、观察性研究和前瞻性临床试验的核心结果。支气管扩张剂可逆性以及预支气管扩张剂和后支气管扩张剂 FEV1 也是研究人群特征和观察性研究的核心结果。
小组委员会认为肺生理学结果在哮喘中具有重要意义,并提出肺功能结果作为所有未来由 NIH 发起的哮喘临床研究的核心结果。